Published in Nature on November 13, 1997
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 4.67
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med (2003) 3.46
A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med (2001) 3.18
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A (2000) 2.41
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest (2000) 2.32
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol (2007) 2.25
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Bone destruction in arthritis. Ann Rheum Dis (2002) 2.15
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Mechanisms of tooth eruption and orthodontic tooth movement. J Dent Res (2008) 2.09
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med (2002) 2.07
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol (2009) 2.01
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol (2000) 1.99
TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med (2000) 1.90
Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol (2006) 1.89
Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A (2003) 1.87
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A (2001) 1.81
NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res (2001) 1.76
TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med (1999) 1.67
Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol (2006) 1.67
Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int J Exp Pathol (2000) 1.66
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med (2015) 1.66
The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med (2010) 1.59
RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem (2010) 1.58
The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol (2009) 1.57
CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med (2002) 1.56
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol (2002) 1.53
A genome-wide association study of myasthenia gravis. JAMA Neurol (2015) 1.52
NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol Cell Biol (2005) 1.52
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Control of RANKL gene expression. Bone (2009) 1.47
Tumor necrosis factor alpha is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection. J Exp Med (1999) 1.47
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest (2001) 1.45
Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells. BMC Complement Altern Med (2017) 1.39
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol (2002) 1.38
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci U S A (2002) 1.34
Receptor-mediated choreography of life and death. J Clin Immunol (2003) 1.33
The gene for cherubism maps to chromosome 4p16. Am J Hum Genet (1999) 1.32
B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci U S A (2000) 1.31
Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest (2000) 1.30
Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet (2005) 1.30
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest (2000) 1.29
Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int (2013) 1.29
An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med (2003) 1.29
Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol (2005) 1.26
Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol (2005) 1.25
HIV: inflammation and bone. Curr HIV/AIDS Rep (2012) 1.23
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis (2002) 1.21
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) (2013) 1.20
Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 (2014) 1.20
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res (2002) 1.16
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest (2006) 1.15
Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest (2000) 1.15
Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab (2014) 1.15
Chronic inflammation in cancer development. Front Immunol (2012) 1.14
Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther (2007) 1.14
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci U S A (2011) 1.13
Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun (2005) 1.13
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
A novel ubiquitin-binding protein ZNF216 functioning in muscle atrophy. EMBO J (2006) 1.12
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res (2004) 1.12
Interactions between immune and bone cells: new insights with many remaining questions. J Clin Invest (2000) 1.11
Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol (2009) 1.11
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest (2000) 1.09
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res (2000) 1.07
Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front Immunol (2012) 1.07
Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther (2002) 1.06
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med (1994) 8.97
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J (1994) 5.69
Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A (1999) 5.66
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 5.06
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90
Distribution and abundance of insertion sequences among natural isolates of Escherichia coli. Genetics (1987) 4.77
Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell (1990) 4.15
Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell (1990) 3.98
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J (1995) 3.59
cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science (1988) 3.56
Three-dimensional structure of beta-galactosidase from E. coli. Nature (1994) 3.46
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
Fas transduces activation signals in normal human T lymphocytes. J Exp Med (1993) 3.04
Cloning, sequence and expression of human interleukin-2 receptor. Nature (1985) 3.02
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell (1990) 2.95
Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol (1997) 2.89
A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J (1991) 2.85
The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem (1987) 2.78
Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J (1991) 2.56
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. J Biol Chem (1988) 2.46
Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci U S A (1989) 2.46
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med (1995) 2.19
Secretion of a transplantation-related antigen. Cell (1983) 2.12
A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol (1997) 2.09
Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med (2000) 2.09
Cloning, sequence and expression of bovine interleukin 1 alpha and interleukin 1 beta complementary DNAs. Mol Immunol (1988) 1.97
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem (1996) 1.89
Soluble forms of CD40 inhibit biologic responses of human B cells. J Immunol (1992) 1.88
The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem (1998) 1.86
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature (1994) 1.85
IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol (1995) 1.84
IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol (1999) 1.77
Tissue-specific expression of an unusual H-2 (class I)-related gene. Proc Natl Acad Sci U S A (1982) 1.76
Mouse thymus dendritic cells: kinetics of development and changes in surface markers during maturation. Eur J Immunol (1995) 1.71
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol (1995) 1.70
Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol (1995) 1.69
Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci U S A (1991) 1.66
Modulating the immune response with dendritic cells and their growth factors. Trends Immunol (2001) 1.66
Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J Biol Chem (1990) 1.65
Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains. J Exp Med (1990) 1.63
Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol (2000) 1.58
Normal human IgD+IgM- germinal center B cells can express up to 80 mutations in the variable region of their IgD transcripts. Immunity (1996) 1.56
A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity (1998) 1.52
Expression, purification and characterization of recombinant murine granulocyte-macrophage colony-stimulating factor and bovine interleukin-2 from yeast. Gene (1987) 1.50
Phylogenetic analysis using insertion sequence fingerprinting in Escherichia coli. Mol Biol Evol (1989) 1.49
Three classes of mouse H-2 messenger RNA distinguished by analysis of cDNA clones. Nature (1982) 1.48
The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J Virol (1998) 1.46
ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol (2001) 1.37
The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol (1998) 1.36
Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor. J Exp Med (1996) 1.36
Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med (1997) 1.35
Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood (1991) 1.35
Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A (1994) 1.31
Cloning of the low-affinity murine granulocyte-macrophage colony-stimulating factor receptor and reconstitution of a high-affinity receptor complex. Proc Natl Acad Sci U S A (1992) 1.28
Induction of an interleukin-1 receptor (IL-1R) on monocytic cells. Evidence that the receptor is not encoded by a T cell-type IL-1R mRNA. J Biol Chem (1990) 1.26
Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. J Immunol (1996) 1.25
Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A (1994) 1.24
The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol Rev (2001) 1.24
Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J (1994) 1.24
The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int Immunol (1999) 1.24
Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 alpha and 1 beta. Proc Natl Acad Sci U S A (1987) 1.20
LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine Growth Factor Rev (2000) 1.20
Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med (1998) 1.20
The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood (1995) 1.20
The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol (2000) 1.20
Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Proc Natl Acad Sci U S A (1994) 1.19
Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell (1991) 1.18
Cloning, sequence, and expression of bovine interferon-gamma. J Immunol (1986) 1.17
Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv Exp Med Biol (1997) 1.14
Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth Differ (1991) 1.12
FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol (1997) 1.12
IS103, a new insertion element in Escherichia coli: characterization and distribution in natural populations. Genetics (1989) 1.10
Cloning, sequence, and expression of bovine interleukin 2. Proc Natl Acad Sci U S A (1986) 1.10
Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro. Immunol Rev (1991) 1.09
Modeling protein loops using a phi i + 1, psi i dimer database. Protein Sci (1995) 1.09
Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol (1991) 1.09
Stably transmitted triple-promoter retroviral vectors and their use in transformation of primary mammalian cells. Mol Cell Biol (1988) 1.09
Phosphorylation of the human interleukin-2 receptor and a synthetic peptide identical to its C-terminal, cytoplasmic domain. J Biol Chem (1986) 1.07
Ligands for the receptor tyrosine kinases hek and elk: isolation of cDNAs encoding a family of proteins. Oncogene (1995) 1.07
T-cell growth factor P40 promotes the proliferation of myeloid cell lines and enhances erythroid burst formation by normal murine bone marrow cells in vitro. Blood (1990) 1.05
Human macrophage-colony stimulating factor: alternative RNA and protein processing from a single gene. Mol Immunol (1988) 1.05
Reconstitution of a functional interleukin (IL)-7 receptor demonstrates that the IL-2 receptor gamma chain is required for IL-7 signal transduction. Eur J Immunol (1995) 1.03
Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J Immunol (1989) 1.02
Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene (1994) 1.02
Gene expression profiling of Spodoptera frugiperda hemocytes and fat body using cDNA microarray reveals polydnavirus-associated variations in lepidopteran host genes transcript levels. BMC Genomics (2006) 1.01
Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett (1997) 1.00
The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Clin Exp Immunol (1996) 0.99